<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="23685"><DrugName>BAY-Z-4305</DrugName><DrugSynonyms><Name><Value>BAY-Z-4305</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14455">Bayer AG</CompanyOriginator><CompaniesSecondary><Company id="14455">Bayer AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="159">HIV-1 infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="1016">HIV-1 reverse transcriptase inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-19T08:39:43.000Z</LastModificationDate><ChangeDateLast>2003-05-28T12:02:08.000Z</ChangeDateLast><AddedDate>1999-06-01T16:30:17.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; was investigating the non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), &lt;ulink linkID="23685" linkType="Drug"&gt;BAY-Z-4305&lt;/ulink&gt;, for the potential treatment of HIV-1 infection [&lt;ulink linkID="326487" linkType="reference"&gt;326487&lt;/ulink&gt;]. By December 2000, &lt;ulink linkID="23685" linkType="Drug"&gt;BAY-Z-4305&lt;/ulink&gt; was no longer in development [&lt;ulink linkID="392575" linkType="reference"&gt;392575&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound is effective in the nanomolar range against HIV-1 in cell culture with a high specificity. RT activity was inhibited at 0.1 to 1.0 microM. The drug is cross resistant to other NNRTI-resistant HIV isolates. A favorable pharmacokinetic profile and good tolerability are further characteristics of the compound which was available for licensing [&lt;ulink linkID="326487" linkType="reference"&gt;326487&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="159">HIV-1 infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-07T00:00:00.000Z</StatusDate><Source id="392575" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-01T16:30:17.000Z</StatusDate><Source id="326487" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00940"><Name>HIV-1 reverse transcriptase</Name><SwissprotNumbers><Swissprot>P03366</Swissprot><Swissprot>P03367</Swissprot><Swissprot>P03369</Swissprot><Swissprot>P04585</Swissprot><Swissprot>P04586</Swissprot><Swissprot>P04587</Swissprot><Swissprot>P04588</Swissprot><Swissprot>P04589</Swissprot><Swissprot>P05959</Swissprot><Swissprot>P05960</Swissprot><Swissprot>P05961</Swissprot><Swissprot>P12497</Swissprot><Swissprot>P12498</Swissprot><Swissprot>P12499</Swissprot><Swissprot>P18802</Swissprot><Swissprot>P20875</Swissprot><Swissprot>P20892</Swissprot><Swissprot>P24740</Swissprot><Swissprot>P35963</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>